FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- 31 August 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (13), 1306-1315
- https://doi.org/10.1016/s1470-2045(15)00122-9
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerThe New England Journal of Medicine, 2013
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerCancer, 2011
- Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutationInternational Journal of Cancer, 2011
- Detection of KRAS and BRAF Mutations in Colorectal Carcinoma: Roles for High-Sensitivity Locked Nucleic Acid-PCR Sequencing and Broad-Spectrum Mass Spectrometry GenotypingThe Journal of Molecular Diagnostics, 2011
- A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodesBMC Cancer, 2010
- Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line ChemotherapyJournal of Clinical Oncology, 2007
- Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord OvestJournal of Clinical Oncology, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000